Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Iovance Reports 59.1% Response in Biomarker-Enriched Lung Cancer Subgroup

Neutral Impact 3 of 5 product/contract Written later

Iovance updated results from Cohorts 1 and 2 of its Phase 2 IOV-LUN-202 trial in previously treated non-squamous metastatic non-small-cell lung cancer, reporting a 24.6% objective response rate in 69 patients, consistent with the 25.6% previously reported. The company also introduced a retrospectively identified biomarker subgroup with a 59.1% response rate, a precision strategy that could change how the lung cancer program is developed and how the company plans its next trial.

Key points

  • Broader population: 24.6% objective response rate (17 of 69 patients), consistent with the 25.6% rate in 39 patients previously reported.
  • Retrospective biomarker subgroup (KRAS wild-type, HER2 wild-type, current or former smoker): 59.1% response rate (13 of 22 patients), including both complete responses.
  • POSITILITY study to begin enrollment in November 2026; supplemental Biologics License Application for non-squamous mNSCLC planned for 2027, subject to FDA discussions.

The filing

CompanyIOVANCE BIOTHERAPEUTICS, INC. (IOVA)
Form8-K, current report
Filed with the SECOct 29, 2026, 5:00 PM ET
Accession number0001104659-26-120261

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.